Maria Papaleontiou

Maria Papaleontiou

Auto-generated profile, based on publicly available information

Maria Papaleontiou

Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, North Campus Research Complex, 2800 Plymouth Road, Bldg. 16, Rm G024W, Ann Arbor, MI 48109

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2010 in Journal of the American Geriatrics Society
Verified
Journal Article
Closed access
PDF file
MPMaria Papaleontiou
Maria Papaleontiou
JHJr Charles R. Henderson
Jr Charles R. Henderson
BTBarbara J. Turner
Barbara J. Turner
AMAlison A. Moore
Alison A. Moore
YOYelena Olkhovskaya
Yelena Olkhovskaya
CRCary Reid
Cary Reid

13 October 2023 in Thyroid®
Verified
Journal Article
Open access
CSCatherine F. Sinclair
Catherine F. Sinclair
JBJung Hwan Baek
Jung Hwan Baek
KHKathleen E. Hands
Kathleen E. Hands
SHSteven P. Hodak
Steven P. Hodak
THTimothy C. Huber
Timothy C. Huber
JKJennifer H. Kuo
Jennifer H. Kuo
Background: The primary goal of this interdisciplinary consensus statement is to provide a framework for the safe adoption and implementation of ablation technologies for benign thyroid nodules. Summary: This consensus statement is organized around three key themes: (1) safety of ablation techniques and their implementation, (2) optimal skillset criteria for proceduralists performing ablative procedures, and (3) defining expectations of success for this treatment option given its unique risks and benefits. Ablation safety considerations in pre-procedural, peri-procedural, and post-procedural settings are discussed, including clinical factors related to patient selection and counseling, anesthetic and technical considerations to optimize patient safety, peri-procedural risk mitigation strategies, post-procedural complication management, and safe follow-up practices. Prior training, knowledge, and steps that should be considered by any physician who desires to incorporate thyroid nodule ablation into their practice are defined and discussed. Examples of successful clinical practice implementation models of this emerging technology are provided. Conclusions: Thyroid ablative procedures provide valid alternative treatment strategies to conventional surgical management for a subset of patients with symptomatic benign thyroid nodules. Careful patient and nodule selection are critical to the success of these procedures as is extensive pre-procedural patient counseling. Although these emerging technologies hold great promise, they are not without risk and require the development of a unique skillset and environment for optimal, safe performance and consistent outcomes.

11 March 2008 in Pain Medicine
Verified
Journal Article
Open access
PDF file
CRCary Reid
Cary Reid
MPMaria Papaleontiou
Maria Papaleontiou
AOAnthony Ong
Anthony Ong
RBRisa Breckman
Risa Breckman
EWElaine Wethington
Elaine Wethington
KPKarl Pillemer
Karl Pillemer
Context. Self-management strategies for pain hold substantial promise as a means of reducing pain and improving function among older adults with chron

14 July 2011 in BMC Geriatrics
Verified
Journal Article
Open access
PDF file
ASAerin Spitz
Aerin Spitz
AMAlison A Moore
Alison A Moore
MPMaria Papaleontiou
Maria Papaleontiou
EGEvelyn Granieri
Evelyn Granieri
BTBarbara J Turner
Barbara J Turner
CRCary Reid
Cary Reid
Background: The use of opioid medications as treatment for chronic non-cancer pain remains controversial. Little information is currently available regarding healthcare providers' attitudes and beliefs about this practice among older adults. This study aimed to describe primary care providers' experiences and attitudes towards, as well as perceived barriers and facilitators to prescribing opioids as a treatment for chronic pain among older adults. Methods: Six focus groups were conducted with a total of 23 physicians and three nurse practitioners from two academically affiliated primary care practices and three community health centers located in New York City. Focus groups were audiotape recorded and transcribed. The data were analyzed using directed content analysis; NVivo software was used to assist in the quantification of identified themes. Results: Most participants (96%) employed opioids as therapy for some of their older patients with chronic pain, although not as first-line therapy. Providers cited multiple barriers, including fear of causing harm, the subjectivity of pain, lack of education, problems converting between opioids, and stigma. New barriers included patient/family member reluctance to try an opioid and concerns about opioid abuse by family members/caregivers. Studies confirming treatment benefit, validated tools for assessing risk and/or dosing for comorbidities, improved conversion methods, patient education, and peer support could facilitate opioid prescribing. Participants voiced greater comfort using opioids in the setting of delivering palliative or hospice care versus care of patients with chronic pain, and expressed substantial frustration managing chronic pain. Conclusions: Providers perceive multiple barriers to prescribing opioids to older adults with chronic pain, and use these medications cautiously. Establishing the long-term safety and efficacy of these medications, generating improved prescribing methods, and implementing provider and patient educational interventions could help to improve the management of chronic pain in later life.

28 April 2017 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
MPMaria Papaleontiou
Maria Papaleontiou
DHDavid T. Hughes
David T. Hughes
CGCui Guo
Cui Guo
MBMousumi Banerjee
Mousumi Banerjee
MHMegan R. Haymart
Megan R. Haymart
Context: As thyroid cancer incidence rises, more patients undergo thyroid surgery. Although postoperative complication rates have been reported in single institution studies, population-based data are limited. Objective: To determine thyroid cancer surgery complication rates and identify at-risk populations. Design/Setting/Patients: Using the Surveillance, Epidemiology, and End Results–Medicare database, we evaluated general complications within 30 days and thyroid surgery–specific complications within 1 year in 27,912 patients who underwent surgery for differentiated or medullary thyroid cancer between 1998 and 2011. Multivariable analyses of patient characteristics associated with postoperative complications were performed. Main Outcome Measures: General and thyroid surgery–specific complications. Results: Overall, 1820 (6.5%) patients developed general postoperative complications and 3427 (12.3%) developed thyroid surgery–specific complications. In multivariable analyses, general and thyroid surgery–specific complications were significantly higher in patients >65 years [odds ratio (OR), 2.61; 95% confidence interval (CI), 2.31 to 2.95; OR, 3.12; 95% CI, 2.85 to 3.42], those with a Charlson/Deyo comorbidity score of 1 (OR, 2.40; 95% CI, 1.66 to 3.49; OR, 1.88; 95% CI, 1.53 to 2.31) and ≥2 (OR, 7.05; 95% CI, 5.33 to 9.56; OR, 3.62; 95% CI, 3.11 to 4.25), and those with regional (OR, 1.18; 95% CI, 1.03 to 1.35; OR, 1.31; 95% CI, 1.19 to 1.45) or distant disease (OR, 2.83; 95% CI, 2.30 to 3.47; OR, 1.85; 95% CI, 1.54 to 2.21), respectively. Conclusions: The rates of thyroid cancer surgery complications are higher than predicted, and patients with older age, more comorbidities, and advanced disease are at greatest risk. Efforts to reduce complications are needed.

12 May 2022 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
JEJosh M. Evron
Josh M. Evron
SHScott L. Hummel
Scott L. Hummel
DRDavid Reyes-Gastelum
David Reyes-Gastelum
MHMegan R. Haymart
Megan R. Haymart
MBMousumi Banerjee
Mousumi Banerjee
MPMaria Papaleontiou
Maria Papaleontiou
Despite widespread efforts at prevention and advances in diagnosis and treatment, cardiovascular disease remains the leading cause of death in the United States and affects nearly 50% of individuals in the US aged 20 years or older.1,2 In addition, it is estimated that the annual financial burden of heart disease in the United States is more than $200 billion.1 Although many cardiovascular risk factors are known (eg, hypertension, diabetes, and smoking), the persistent public health impact of cardiovascular disease mandates a more complete understanding of novel risk factors.1,3 A recent study has shown that the intensity of thyroid hormone treatment is a modifiable risk factor for incident atrial fibrillation and stroke4; however, its association with cardiovascular mortality remains unclear.